NCT03144128 is a NA clinical trial of Vitamin D in Cancer Cachexia, sponsored by David Travis Thomas.

Who is sponsoring NCT03144128?

NCT03144128 is sponsored by David Travis Thomas.

What drugs are being tested in NCT03144128?

Interventions in NCT03144128: Vitamin D, Placebo.

What condition does NCT03144128 study?

NCT03144128 studies Cancer Cachexia, Vitamin D Deficiency.

Is NCT03144128 still recruiting?

NCT03144128 is currently completed. Last updated 14 October 2020.

Last reviewed 2020-10-14 · How we verify

NCT03144128

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Vitamin D for Muscle Metabolic Function in Cancer Cachexia

Completed NA Last updated 14 October 2020

What this trial tests

NA trial testing Vitamin D in Cancer Cachexia in 1 participant. Completed in 13 September 2018.

Timeline

23 May 2018

Primary endpoint
13 September 2018

13 September 2018

Quick facts

Lead sponsor	David Travis Thomas
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	supportive care
Enrollment	1
Start date	23 May 2018
Primary completion	13 September 2018
Estimated completion	13 September 2018
Sites	1 location across United States

Drugs / interventions tested

Vitamin D
Placebo

Conditions studied

Cancer Cachexia — all drugs for Cancer Cachexia →
Vitamin D Deficiency — all drugs for Vitamin D Deficiency →

Sponsor

David Travis Thomas — full company profile →

Who can join

Adults 45 to 75, any sex, with Cancer Cachexia or Vitamin D Deficiency. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The proposed study is aimed at examining mitochondrial function as a potential target of action of vitamin D on muscle metabolism, size, and strength in preventing the progression of cachexia. This is the first clinical trial designed to understand the effects of vitamin D on muscle metabolic dynamics driving dysfunction in cachectic muscle. Our preliminary data suggest that vitamin D promotes lipid partitioning and muscle metabolic function, which the investigators hypothesize, will mitigate cachexia via improved muscle health and quality that translates into reduced fatigue, and improved patient resilience to multimodal cancer therapy.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting the JAK2/STAT3 Pathway-Can We Compare It to the Two Faces of the God Janus?
Jaśkiewicz A, Domoradzki T, Pająk B. · · 2020 · cited 32× · PMID 33158194 · DOI 10.3390/ijms21218261
Role of Mitochondria-Cytoskeleton Interactions in the Regulation of Mitochondrial Structure and Function in Cancer Stem Cells.
Kim J, Cheong JH. · · 2020 · cited 32× · PMID 32674438 · DOI 10.3390/cells9071691
Targeting cancer cachexia: Molecular mechanisms and clinical study.
Wang YF, An ZY, Lin DH, Jin WL. · · 2022 · cited 27× · PMID 36105371 · DOI 10.1002/mco2.164
Vitamin D, immune microenvironment, and cervical lesions: mechanisms and therapeutic strategies from polyps to carcinoma.
He Z, Du C. · · 2025 · PMID 41245397 · DOI 10.3389/fnut.2025.1688910

Verify or expand the search:

Other trials of Vitamin D

Trials testing the same drug.

NCT07366086 — Pediatric Safety Follow-up Study of Prior Treatment With Romosozumab for Osteogenesis Imperfecta · Phase 3 · recruiting
NCT07458815 — Vitamin D for Acute Intracerebral Hemorrhage · NA · not yet recruiting
NCT07491965 — Association Between Benign Paroxysmal Positional Vertigo and Vitamin D Deficiency . · not yet recruiting
NCT07400757 — Statin and Vitamin D Treatment in Patients With Thyroid Eye Disease · NA · not yet recruiting
NCT07293910 — Vonoprazan vs Proton Pump Inhibitor With Vitamin D or Probiotics Based Triple Therapy for Eradication of Helicobacter Py · Phase 2 · recruiting

Other recruiting trials for Cancer Cachexia

Currently open trials in the same condition.

NCT07237464 — To Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of GB18 Injection in Health · Phase 1 · recruiting
NCT07072728 — Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder · Phase 2 · recruiting
NCT06898255 — A Phase I Study to Evaluate GFS202A in Advanced Solid Tumor Patients With Pre-cachexia or Cachexia · Phase 1 · recruiting
NCT06868849 — A Study of JMT203 in Patients With Cancer Cachexia · Phase 1 · recruiting
NCT05915325 — Physical Training for Elderly Cancer Patients With Cachexia · NA · active not recruiting

Other David Travis Thomas trials

Trials by the same sponsor.

NCT04283630 — Nitrate and Vitamin C on Vascular Health Oxidative Stress · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03144128 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by David Travis Thomas
Last refreshed: 14 October 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03144128.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing